Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Archives of Internal Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7993148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial.

  1993cited by this paper
• Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?

  1993cited by this paper
• Intention-to-treat analysis: implications for quantitative and qualitative research.

  1992cited by this paper
• Differential misclassification arising from nondifferential errors in exposure measurement.

  1991cited by this paper
• Estimating the effect of the run-in on the power of the Physicians' Health Study.

  1991cited by this paper
• On estimating efficacy from clinical trials.

  1991cited by this paper
• Analysis of clinical trials by treatment actually received: is it really an option?

  1991cited by this paper
• Biochemical markers of compliance in the Physicians' Health Study.

  1990cited by this paper
• The run-in period in clinical trials. The effect of misclassification on efficiency.

  1990cited by this paper
• Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models.

  1986cited by this paper
• Differential inhibition of prostacyclin production and platelet aggregation by aspirin.

  1979cited by this paper
• Inhibition of platelet prostaglandin synthetase by oral aspirin.

  1978cited by this paper
• Effects of salicylates on human platelets.

  1968cited by this paper

• Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study

  2025cites this paper
• A Thorough Literature Review of the Potential Benefits and Drawbacks of Long-Term Aspirin Use for the Primary Prevention of Cardiovascular Disease.

  2024cites this paper
• The Healthy User Effect in Pharmacoepidemiology.

  2024cites this paper
• Analysis of antiplatelet therapy adherence in patients with ischemic cerebral stroke

  2023cites this paper
• Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?

  2021cites this paper
• Aspirin in primary prevention for patients with diabetes: Still a matter of debate

  2018cites this paper
• Randomized controlled trials: who fails run-in?

  2015cites this paper
• Causal inference methods to assess safety upper bounds in randomized trials with noncompliance

  2015cites this paper
• Aspirin for Cardioprotection and Strategies to Improve Patient Adherence

  2014cites this paper
• The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis

  2014cites this paper
• Statements of the Malaysian Society of Gastroenterology & Hepatology and the National Heart Association of Malaysia task force 2012 working party on the use of antiplatelet therapy and proton pump inhibitors in the prevention of gastrointestinal bleeding

  2013cites this paper
• High Platelet Reactivity and Antiplatelet Therapy Resistance

  2012cites this paper
• Adherence and dosing frequency of common medications for cardiovascular patients.

  2012cites this paper
• How patient cost-sharing trends affect adherence and outcomes: a literature review.

  2012cites this paper
• Overcoming aspirin treatment failure in diabetes

  2012cites this paper
• Antiplatelet effect of aspirin in patients with coronary artery disease.

  2012cites this paper
• Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid

  2011cites this paper
• Cost‐effectiveness analysis: cardiovascular benefits of proton pump inhibitor co‐therapy in patients using aspirin for secondary prevention

  2011cites this paper
• The DETECT adherence score – structure and psychometric exploration of a novel approach to measure adherence to drug and non‐drug interventions in primary care

  2011cites this paper
• Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance".

  2010cites this paper
• Placebo Adherence and Its Association with Morbidity and Mortality in the Studies of Left Ventricular Dysfunction

  2010cites this paper
• Adherence, Placebo Effects, and Mortality

  2010cites this paper
• Low-Dose Aspirin Therapy for Cardiovascular Prevention

  2010cites this paper
• The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk

  2010cites this paper
• Resistance or resistors? Has Ohm's law come to antiplatelet therapy?

  2010cites this paper
• Adherence to Medicines in the Older-Aged with Chronic Conditions

  2010cites this paper
• Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.

  2009cites this paper
• New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors.

  2009cites this paper
• What is the risk of cardiovascular morbidity?

  2008cites this paper
• Biochemical evaluation of the antiplatelet effect of aspirin in patients at different levels of cardiovascular risk.

  2008cites this paper
• The benefit of aspirin therapy in type 2 diabetes: what is the evidence?

  2008cites this paper
• Life saving early and immediate aspirin: too little too late

  2008cites this paper
• Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease

  2007cites this paper
• Design of Cluster-Randomized Trials of Quality Improvement Interventions Aimed at Medical Care Providers

  2007cites this paper
• Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies

  2006cites this paper
• Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.

  2006cites this paper
• A meta-analysis of the association between adherence to drug therapy and mortality

  2006cites this paper
• My health: whose responsibility? Low-dose aspirin and older people

  2006cites this paper
• Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.

  2005cites this paper
• Failure of Aspirin to Prevent Atherothrombosis

  2004cites this paper
• Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

  2003cites this paper
• Building empowering partnerships for interprofessional care

  2003cites this paper
• Giving aspirin and ibuprofen after myocardial infarction

  2003cites this paper
• Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs

  2003cites this paper
• Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis

  2002cites this paper
• Counting recurrent events in cancer research.

  2001cites this paper
• Paradoxical Relations of Drug Treatment with Mortality in Older Persons

  2001cites this paper
• Microalbuminuria screening for patients having type 2 diabetes mellitus: who wants to participate?

  2001cites this paper
• Patient-centered processes of care and long-term outcomes of myocardial infarction

  2001cites this paper
• Aspirin: past, present and future.

  2001cites this paper
• Inclusion of Older Women in Randomized Clinical Trials: Factors Associated with Taking Study Medication in the Fracture Intervention Trial

  2000cites this paper
• Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.

  2000cites this paper
• Potential clinical and economic effects of homocyst(e)ine lowering.

  2000cites this paper
• Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians' health study.

  2000cites this paper
• Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study

  1998cites this paper
• Concerns about run-in periods in randomized trials.

  1998cites this paper
• Partnerships with Patients: The Pros and Cons of Shared Clinical Decision-Making

  1997cites this paper
• Intermediate Markers and Molecular Genetics of Lung Carcinogenesis.

  1997cites this paper
• Patients' prerogatives and perceptions of benefit

  1996cites this paper
• Ways of measuring rates of recurrent events

  1996cites this paper
• Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring.

  1996cites this paper
• The placebo effect in cardiovascular disease.

  1996cites this paper